Universal Health International Group Holding Limited is an investment holding company principally engaged in the distribution and retail of drugs and other pharmaceutical products in the northeastern region of the People's Republic of China. The company operates through three main segments: retail business, involving the retail sale of drugs and pharmaceutical products through drug retail chains; distribution business, focusing on the wholesale distribution of drugs and pharmaceutical products to hospitals, clinics, and other retailers; and others, primarily comprising investments in related companies. Its extensive product portfolio encompasses Chinese patent medicines; chemical preparations; antibiotics and biochemical drugs; traditional Chinese medicine decoction pieces; biological products; protein assimilation preparations; peptide hormones; disinfection products; blood products; medical equipment; prepackaged food; health care products; nutritional food; stereotyped packaging cosmetics; daily necessities; family planning supplies, such as contraceptives and utensils; and dairy products, including infant formula milk powder; while it also provides storage services for pharmaceuticals. Founded in 1998 and headquartered at No. 14-1, Bei Yi Zhong Road, Tiexi District, Shenyang, China, the company primarily serves the domestic Chinese market with approximately 842 employees. In recent developments, Universal Health International Group Holding Limited proposes amendments to its articles of association to modernize governance, enabling electronic communications, hybrid meetings, electronic payments, and treasury share management in line with updated Listing Rules and Cayman Islands laws, subject to shareholder approval at the upcoming annual general meeting; additionally, it reports fiscal year 2025 results with revenue of RMB711.5 million, reflecting a 34.7% year-on-year decline amid a shift to a net loss of RMB26.06 million attributable to shareholders.